Trilaciclib to protect bone marrow during chemoradiation
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a drug called trilaciclib, given along with standard chemotherapy (etoposide plus cisplatin or carboplatin) and radiation. The goal is to see if trilaciclib can help protect your bone marrow from the side effects of treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have limited-stage small cell lung cancer (it has not spread widely).
- You should be able to do most daily activities yourself (ECOG score 0, 1, or 2).
- Your liver, kidneys, and bone marrow must be working well without recent transfusions or growth-factor shots.
- You cannot have active infections, autoimmune diseases, or other cancers that are still present.
- You cannot have brain metastases that cause symptoms or need treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug trilaciclib can reduce low blood cell counts caused by chemotherapy in people with Ewing's sarcoma. If you qualify, you may receive a medication that could help protect your bone marrow during treatment.
This study tests whether adding trilaciclib to a new chemotherapy (sacituzumab tirumotecan) can help people with EGFR-mutant lung cancer that keeps growing after certain targeted treatments. The goal is to see if it slows the cancer and reduces side effects.
This study tests a drug called Trilaciclib to see if it can prevent low blood cell counts caused by a type of chemotherapy called topoisomerase I inhibitor ADCs. If you are getting this kind of chemo, you may be able to join.
This trial tests a new drug combination for people with locally advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if adding trilaciclib to standard chemo and immunotherapy works better before surgery.
This trial tests adding trilaciclib to standard chemotherapy before surgery for patients with newly diagnosed, high-grade osteosarcoma. Trilaciclib may help protect healthy cells during chemo treatment.
This trial tests a drug called trilaciclib, given before chemotherapy to protect your bone marrow (where blood cells are made). It is for people with advanced bile duct or pancreatic cancer who are about to start chemotherapy.
Hear when a new Myelosuppression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.